insofar as it relates to the termination of a material definitive agreement of the Company.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under “

Entry into a Material Definitive Agreement. Entry into Credit Agreement On August 13, 2026, Illumina, Inc. (“Illumina” or the “Company”) entered into a credit agreement (the “Credit Agreement”) among the Company, as the borrower, the lenders from time to time party thereto, Bank of America, N.A., as administrative agent, an issuing bank and the swingline lender, and the other issuing banks from time to time party thereto. The Credit Agreement provides for a $1,000 million senior unsecured fiv…

Other Events. Effective August 21, 2025, Illumina, Inc. (the “Company”) entered into a Release Agreement with the plaintiffs and all named defendants reflecting the terms of the settlement of the litigation captioned Icahn Partners LP, et al., v. Francis DeSouza, et al. , C.A. No. 2023-1045-PAF (the “Action”) in the Court of Chancery of the State of Delaware (the “Court”), relating to the Company’s acquisition of GRAIL, Inc. The Defendants Francis deSouza, John Thompson, Frances Arnold, Carol…

Results of Operations and Financial Condition. On July 30, 2026, Illumina, Inc. (the “Company”) issued a press release announcing financial results for the second quarter ended June 28, 2026. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to t…

Director — Daniel M. Skovronsky, M.D., Ph.D.: Dr. Skovronsky was appointed to the Board of Directors, increasing its size from nine to ten members.

Results of Operations and Financial Condition. On April 30, 2026, Illumina, Inc. (the “Company”) issued a press release announcing financial results for the first quarter ended March 29, 2026. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to…

Other Events. On April 28, 2026, the Company’s Board of Directors authorized a new share repurchase program for up to $1.5 billion of the Company’s common stock (the “2026 Repurchase Program”). The 2026 Repurchase Program is in addition to the $1.5 billion repurchase program authorized by the Board of Directors in August 2024, under which approximately $314 million of repurchase capacity remained as of April 29, 2026. Table of Contents

Director — Drs. Frances Arnold, Robert S. Epstein and Gary S. Guthart: Three directors are retiring from the board.

Results of Operations and Financial Condition. On February 5, 2026, Illumina, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and fiscal year ended December 28, 2025. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or…

Completion of Acquisition or Disposition of Assets. As previously disclosed in the Current Report on Form 8-K filed by Illumina, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on June 23, 2025, the Company entered into a Stock Purchase Agreement, dated as of June 22, 2025 (the “Purchase Agreement”), with Standard BioTools Inc. (“Standard BioTools”), a Delaware corporation, pursuant to which the Company agreed to acquire (the “Transaction”) from Standard BioTools…

Results of Operations and Financial Condition. On January 13, 2026, in advance of a public webcast presentation at the J.P. Morgan Healthcare Conference in San Francisco, California, Illumina, Inc. (the "Company") issued a press release regarding the Company's unaudited preliminary financial results for the fourth quarter and fiscal year ended December 28, 2025. The webcast is accessible through the Investor Relations section of the Company’s website and will remain available for at least 30…

Chief Commercial Officer — Everett Cunningham: The Chief Commercial Officer is resigning, representing the loss of a senior executive without a named successor in the filing.

Other Events. On November 25, 2025, Illumina, Inc. (“Illumina” or the “Company”) completed a public offering of $500,000,000 aggregate principal amount of its 4.750% notes due 2030 (the “Notes”). Illumina expects to use the net proceeds from the offering for general corporate purposes, which may include repayment of its 5.800% notes due December 12, 2025, of which $500 million aggregate principal amount was outstanding as of September 28, 2025, and the completion of the proposed acquisition o…

Other Events. On November 10, 2025, Illumina, Inc. (“Illumina”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC and BofA Securities, Inc., as representatives of the several underwriters named therein, for the issuance and sale by Illumina of $500,000,000 aggregate principal amount of its 4.750% notes due 2030 (the “Notes”). The offering is expected to close on November 25, 2025, subject to customary closing conditions. Illumina expects to use…

Results of Operations and Financial Condition. On October 30, 2025, Illumina, Inc. (the “Company”) issued a press release announcing financial results for the third quarter ended September 28, 2025. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subje…

Results of Operations and Financial Condition. On July 31, 2025, Illumina, Inc. (the “Company”) issued a press release announcing financial results for the second quarter ended June 29, 2025. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to t…

Entry into a Material Definitive Agreement. On June 22, 2025, Illumina, Inc. (the “Company”) and Standard BioTools Inc. (“Standard BioTools”), a Delaware corporation, entered into a Stock Purchase Agreement (the “Purchase Agreement”). Pursuant to the Purchase Agreement, the Company will acquire (the “Acquisition”) from Standard BioTools (i) all of the issued and outstanding shares in the capital stock of SomaLogic, Inc. (“SomaLogic”), a Delaware corporation, (ii) all of the limited liability…

Director: The filing reports the results of the annual meeting of stockholders, which typically involves the routine election of directors.

Results of Operations and Financial Condition. On May 8, 2025, Illumina, Inc. (the "Company") issued a press release announcing financial results for the first quarter ended March 30, 2025. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the…

Director — Stephen P. MacMillan: The filing reports the resignation of a director and the immediate election of a successor, which is a routine board composition change rather than a loss of senior executive management.

Chief Information Officer — Carissa Rollins: The filing discloses the planned retirement of the Chief Information Officer, which is an orderly succession event rather than a sudden loss of a top executive like the CEO or CFO.

Results of Operations and Financial Condition. On February 6, 2025, Illumina, Inc. (the "Company") issued a press release announcing financial results for the fourth quarter and fiscal year ended December 29, 2024. The full text of the Company’s press release is attached hereto as Exhibit 99.1. The information furnished pursuant to this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or…

Results of Operations and Financial Condition. On January 14, 2025, in advance of a public webcast presentation at the J.P. Morgan Healthcare Conference in San Francisco, California, Illumina, Inc. (the "Company") issued a press release regarding the Company's unaudited preliminary financial results for the fourth quarter and fiscal year ended December 29, 2024. The webcast is accessible through the Investor Relations section of the Company’s website and will remain available for at least 30…

Costs Associated with Exit or Disposal Activities . In Amendment No. 3 filed on May 3, 2024, the Company noted that during Q1 2024, the Company exited a portion of its Foster City campus and another property in San Diego, California. The Company recorded right-of-use asset and leasehold improvement impairment charges of $32 million in the first fiscal quarter of 2024 related to these exits. The Company recorded an additional right-of-use asset impairment of $14 million in Q4 2024 related to t…